Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 101 | ETA2024 | Next issue

46th Annual Meeting of the European Thyroid Association (ETA) 2024

Oral Presentations

Oral Session 1: Topic Highlights

ea0101op-01-01 | Oral Session 1: Topic Highlights | ETA2024

Birth defects in children born to mothers with thyroid disease: biochemical assessment in 20,399 pregnancies substantiates that thyroid function and thyroid autoimmunity are not the causal links

Linding Andersen Stine , Maria Uldall Torp Nanna , Hjelm Lundgaard Maja , Marie Norum Wigh Ida , Vestergaard Peter , Andersen Stig

Objectives: An increased risk of birth defects with the use of antithyroid drugs (ATDs) in early pregnancy has been found in large epidemiological studies. It remains debatable whether this risk associates with the medical treatment, maternal thyroid function or thyroid autoimmunity. We aimed to evaluate the risk of birth defects in relation to maternal thyroid function and thyroid autoantibodies in early pregnancy.Methods: Retrospective study including ...

ea0101op-01-02 | Oral Session 1: Topic Highlights | ETA2024

Reprogramming myeloid bone marrow progenitors in non-medullary thyroid cancer using trained immunity

van Houten Pepijn , Jaeger Martin , van Emst Liesbeth , Changoer Prashant , Mulder Willem , van Engen-van Grunsven Ilse , Bremmers Manita , Franssen Sjoerd , Bonenkamp Han , de Wilt Johannes , Hobo Willemijn , Netea Mihai , Teodora Netea-Maier Romana

Objective: The prognosis of patients with metastasized and radioactive iodine refractory non-medullary thyroid cancer (NMTC) is poor and treatment options are limited. In NMTC tumors, myeloid cells, such as tumor-associated macrophages, are abundant and have an immunosuppressive and pro-tumoral phenotype. Trained immunity describes a specific epigenetic and metabolic program in innate immune cells that leads to an increased proinflammatory phenotype. The aim of the present stu...

ea0101op-01-03 | Oral Session 1: Topic Highlights | ETA2024

Novel Tr-β selective agonist TG68 promotes anti-inflammatory, lipid-lowering and anxiolytic effects

Polini Beatrice , Ricardi Caterina , Di Lupo Francesca , Dettori Cristina , Rapposelli Simona , Saponaro Federica , Chiellini Grazia

Recent advances in drug discovery and development allowed the identification of THRβ-selective thyromimetic TG68 as a powerful lipid lowering and anti-amyloid agent. To expand our knowledge on the therapeutic potential of this novel thyromimetic, we investigated its anti-inflammatory effects in in vitro human models of neuroinflammation. Subsequently, we performed in vivo studies on high fat diet (HFD) obese/insulin resistant mice, a well-established mod...

ea0101op-01-04 | Oral Session 1: Topic Highlights | ETA2024

Unveiling severe adverse events of antithyroid drugs in patients with graves’ disease; a real-world multicenter cohort study

Myoung Shin Soo , Lee Yeji , Choi Jimi , Hyung Kim Yoo , Jin Kim Kyoung , Jin Kim Kyeong , Joo Park Young , Gon Kim Sin

Objectives: Although antithyroid drugs (ATD) offer potent therapeutic benefits for treating Graves’ disease (GD), they can occasionally lead to rare, potentially life-threatening adverse events (AEs), such as agranulocytosis or toxic hepatitis. As the incidence and characteristics of these life-threatening AEs in Korea have not been widely investigated, we aimed to identify the real-world features of ATD-related severe AEs.Method: We analyzed 19,975...

ea0101op-01-05 | Oral Session 1: Topic Highlights | ETA2024

Dabrafenib and trametinib in BRAFV600E anaplastic thyroid cancers: an italian real-word series

Elisei Rossella , Cosimo Durante , Elena Colombo , Claudia Leli , Domenico Salvatore , Laura Fugazzola , Paolo Bossi , Stefania Zovato , Flavia Magri , Alberto Malovini , Laura Deborah Locati

Background: Anaplastic thyroid cancer (ATC) is a lethal tumor with a median overall survival of 6 months. In about 30-40% of cases, a BRAFV600E mutation is present. In 2018 dabrafenib and trametinib (D/T) have been approved in USA for BRAFV600E-mutated ATC, while no approval has been obtained so far in Europe. Up to December 2022, D/T were provided by the company for BRAF-altered cancers within a compassionate named program. Here we report the results fro...

ea0101op-01-06 | Oral Session 1: Topic Highlights | ETA2024

Cut&tag reveals distinct TRA2-specific DNA binding profiles in HIPSC-derived cardiomyocytes

Harting Nina , Ludwik-Shah Katarzyna , Stachelscheid Harald , Surowy Harald , Kilpert Fabian , Koster Johannes , Kaiser Frank J.

Objective: Thyroid hormone receptors (TRs) are important ligand-dependent regulators of thyroid hormone target gene expression. In contrast, the role of TRα2, a thyroid hormone receptor α splice variant that is unable to bind thyroid hormones, remains enigmatic for more than 30 years. However, its evolutionary conservation in eutherian mammals and high expression levels in some cell types as well as under ‘pathological conditions’ such as heart failure stro...